Effimune & Ose Pharma announce proposed merger to create significan immunotherapy player

21 March 2016

effimune-200x200OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune oncology, today announce the signing of a proposed merger agreement.

PR Merger project 24 02 16 VF